References
- Borowitzka MA (1995): Microalgae as sources of pharmaceuticals and other biologically active compounds. Appl Phycol 7: 3–15.
- Burja AM (2001): Marine cyanobacteria prolific source of natural products. Tetrahedron 57: 9437–9477.
- Collins L, Franzblau SG (1997): Microplate Alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium.. Antimicrob Agents Chemother 41: 1004–1009.
- Copp BR (2003): Antimycobacterial natural products. Nat Prod Res 20: 535–537.
- Cragg GM, Newman DJ, Snader KMJ (1997): Natural products in drug discovery and development. J Nat Prod 60: 52–60.
- Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC (1999): Consensus statement on global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282: 677–686.
- Edelman MJ, Gandera DR, Hausner P, Israel V, Thornion D, De Santo J, Doyle LA (2003): Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer. Lung Cancer 39: 197–199.
- Falch BS, Konig GM, Wright AD, Sticher O, Angerhofer CK, Pezzuto JM, Bachmann H (1995): Biological activities of cyanobacteria: Evaluation of extracts and pure compounds. Planta Med 61: 321–328.
- Glombitza KW, Koch M (1989): Secondary metabolites of pharmaceutical potential. In: Algal and Cyanobacterial Biotechnology. eds. Crosswell RC, Rees Tav, Shah N. p. 161–238. Harlow, UK: Longmann Scientific and Technical pp. 161–238.
- Jonge MJ, Van der Gaast A, Planting AS, Van Doorn L, Lems A, Boot I, Wanders J, Satomi M, Verweij J (2005): Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors. Clin Cancer Res 11: 3806–3813.
- Kreitlow S, Sabine M (1999): Cyanobacteria—a potential source of new biologically active substances. J Biotech 70: 61–63.
- Kulik MM (1995): The potential for using cyanobacteria (blue green algae and algae) in the biological control of plant pathogenic bacteria and fungi. Eur J Plant Pathol 10: 585–599.
- Mian P, Heilman J, Burgi HR, Sticher O (2003): Biological screening of terrestrial and fresh water cyanobacterial for antimicrobial activity, brine shrimp lethality and cytotoxicity. Pharm Biol 41: 243–247.
- National Committee for Clinical Laboratory Standards (2000): Susceptibility Testing of Mycobacteria, Nocardia, and other Aerobic Actinomycetes: Tentative Standard M24-T2 NCCLS. 20: No. 26. 2nd ed. vol. 20; no. 26. NCBI Taxonomy Browser, August 30, 2004.
- Patterson GM, Larson LK, Moore RE (1994): Bioactive natural products from blue green algae. J Appl Phycol 6: 151–157.
- Schwartz RE, Hirsch CF, Sesin DF (1990): Pharmaceuticals from cultured algae. J Ind Microbiol 5: 113–124.
- Schopf JW, Walter WR (1983): Archean microfosssils: New evidence of ancient microbes. In: Schopf JW, ed., Earth's Earliest Biosphere: Its Origin and Evolution. Princeton, Princeton University Press, p. 214.
- Simmons TL, Andrianasolo E, McPhail K, Flatt P, William HG (2005): Marine natural products as anticancer drugs. Mol Cancer Ther 4: 333–342.
- Soltani N, Khavari-Nejad RA, Yazdi MT, Shokravi S, Fernández-Valiente E (2005): Screening of soil bacteria for antibacterial and antifungal activity. Pharm Biol 43: 455–459.
- Strohl WR (2000): The role of natural products in a modern drug discovery program. Drug Discovery Today 5: 39–41.